uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of uniQure (NASDAQ:QURE) in a research note issued to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $70.00 price target on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the company. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. Chardan Capital reissued a “buy” rating and set a $35.00 target price on shares of uniQure in a research note on Monday, September 8th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 price target for the company in a research report on Thursday, August 14th. Finally, Cantor Fitzgerald set a $47.00 price target on uniQure in a research report on Wednesday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, uniQure has a consensus rating of “Buy” and an average price target of $42.64.

uniQure Price Performance

QURE stock opened at $47.50 on Wednesday. The business has a fifty day moving average of $15.90 and a two-hundred day moving average of $14.32. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -12.12 and a beta of 0.14. uniQure has a 52-week low of $4.45 and a 52-week high of $51.21.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. The company had revenue of $5.26 million during the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. As a group, research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of QURE. Tower Research Capital LLC TRC lifted its holdings in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,538 shares during the last quarter. Mraz Amerine & Associates Inc. purchased a new stake in uniQure during the 1st quarter worth about $106,000. KLP Kapitalforvaltning AS purchased a new stake in uniQure during the 2nd quarter worth about $117,000. Teacher Retirement System of Texas purchased a new stake in uniQure during the 2nd quarter worth about $151,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in uniQure during the 1st quarter worth about $152,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.